Warning: The NCBI web site requires JavaScript to function. more...
HIV-1 Vif and APOBEC3G: multiple roads to one goal.
Goncalves J, Santa-Marta M.
Retrovirology. 2004 Sep 21;1:28.
Related citations
HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G.
Kremer M, Schnierle BS.
Curr HIV Res. 2005 Oct;3(4):339-44. Review.
HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action.
Santa-Marta M, Aires da Silva F, Fonseca AM, Rato S, Goncalves J.
Mol Immunol. 2007 Jan;44(4):583-90. Epub 2006 Mar 31.
Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G.
Ribeiro AC, Maia e Silva A, Santa-Marta M, Pombo A, Moniz-Pereira J, Goncalves J, Barahona I.
J Virol. 2005 Jan;79(2):823-33.
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, Strebel K, Pathak VK.
Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5652-7. Epub 2004 Mar 30.
Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.
Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D.
J Biol Chem. 2004 Feb 27;279(9):7792-8. Epub 2003 Dec 13.
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.
Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K.
J Virol. 2003 Nov;77(21):11398-407.
Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells.
Kao S, Miyagi E, Khan MA, Takeuchi H, Opi S, Goila-Gaur R, Strebel K.
Retrovirology. 2004 Sep 17;1:27.
HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
Santa-Marta M, da Silva FA, Fonseca AM, Goncalves J.
J Biol Chem. 2005 Mar 11;280(10):8765-75. Epub 2004 Dec 20.
Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
Russell RA, Pathak VK.
J Virol. 2007 Aug;81(15):8201-10. Epub 2007 May 23.
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.
Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF.
Science. 2003 Nov 7;302(5647):1056-60. Epub 2003 Oct 16.
A new approach to an AIDS vaccine: creating antibodies to HIV vif will enable apobec3G to turn HIV-infection into a benign problem.
Jeffrey Fessel W.
Med Hypotheses. 2005;64(2):261-3.
New insights into the role of Vif in HIV-1 replication.
Schröfelbauer B, Yu Q, Landau NR.
AIDS Rev. 2004 Jan-Mar;6(1):34-9. Review.
Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
Liu B, Yu X, Luo K, Yu Y, Yu XF.
J Virol. 2004 Feb;78(4):2072-81.
The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
Conticello SG, Harris RS, Neuberger MS.
Curr Biol. 2003 Nov 11;13(22):2009-13.
Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.
Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, Mallal S.
J Virol. 2006 Sep;80(18):9259-69. Erratum in: J Virol. 2007 Aug;81(16):8843-5.
Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.
Guo F, Cen S, Niu M, Saadatmand J, Kleiman L.
J Virol. 2006 Dec;80(23):11710-22. Epub 2006 Sep 13.
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
Stopak K, de Noronha C, Yonemoto W, Greene WC.
Mol Cell. 2003 Sep;12(3):591-601.
Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
Tian C, Yu X, Zhang W, Wang T, Xu R, Yu XF.
J Virol. 2006 Mar;80(6):3112-5.
Complementary function of the two catalytic domains of APOBEC3G.
Navarro F, Bollman B, Chen H, König R, Yu Q, Chiles K, Landau NR.
Virology. 2005 Mar 15;333(2):374-86.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on